In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists.

Classic antihistamines, namely diphenhydramine, chlorpheniramine, clemastine, perphenazine, hydroxyzine, and tripelennamine, share structural features with substrates and inhibitors of the polymorphic cytochrome P450 (CYP) isozyme CYP2D6. Therefore, the current study was undertaken to characterize the in vitro inhibition of CYP2D6 by these commonly used, histamine H1 receptor antagonists. Microsomal incubations were performed using bufuralol as a specific CYP2D6 substrate and microsomes derived from human cells transfected with CYP2D6 cDNA. Reaction velocities were assessed in the absence and presence of antihistamines (20 microM) at 11 substrate concentrations (1, 2.5, 5, 7.5, 10, 15, 20, 25, 50, 75, and 100 microM), as well as at three nonsaturating substrate concentrations (2.5, 5, and 20 microM) and three inhibitor concentrations (5, 20, and 50 microM). In the presence of all antihistamines, the Vmax and KM of bufuralol 1'-hydroxylation were significantly altered, compared with the uninhibited reaction (p < 0.05). Lineweaver-Burke plots suggested competitive inhibition of the reaction by diphenhydramine and mixed inhibition by all other antihistamines tested. Diphenhydramine and chlorpheniramine, with estimated Ki values of approximately 11 microM, were the weakest inhibitors of CYP2D6 in vitro. Whereas tripelennamine, promethazine, and hydroxyzine were similar in their inhibitory capacities (Ki approximately 4-6 microM), clemastine appeared to be significantly more potent, with a Ki of approximately 2 microM. These data demonstrate that classic histamine H1 receptor antagonists, available in over-the-counter preparations, inhibit CYP2D6 in vitro. Furthermore, the CYP2D6-inhibitory concentrations of these antihistamines are in the range of their expected hepatic blood concentrations, suggesting that, under specific circumstances, clinically relevant interactions between classic antihistamines and CYP2D6 substrates might occur.

[1]  T. Kamataki,et al.  CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. , 1996, Pharmacogenetics.

[2]  S. Imaoka,et al.  Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. , 1995, The Journal of pharmacology and experimental therapeutics.

[3]  N. Vermeulen,et al.  A refined substrate model for human cytochrome P450 2D6. , 1997, Chemical research in toxicology.

[4]  S. Symchowicz,et al.  Metabolism of chlorpheniramine maleate in man. , 1972, The Journal of pharmacology and experimental therapeutics.

[5]  S F Pong,et al.  Comparative studies on distribution, excretion, and metabolism of hydroxyzine-3H and its methiodide-14C in rats. , 1974, Journal of pharmaceutical sciences.

[6]  J. Houston,et al.  Simultaneous determination of promethazine and two of its circulating metabolites by high-performance liquid chromatography. , 1982, Journal of chromatography.

[7]  W. L. Chiou,et al.  Long half-life of chlorpheniramine. , 1979, The New England journal of medicine.

[8]  T. Kronbach,et al.  High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. , 1987, Analytical biochemistry.

[9]  M. Ghoneim,et al.  Diphenhydramine in Orientals and Caucasians , 1980, Clinical pharmacology and therapeutics.

[10]  M. Lennard.  Genetically Determined Adverse Drug Reactions Involving Metabolism , 1993, Drug safety.

[11]  C. Gorodetzky,et al.  The pharmacokinetics of pentazocine and tripelennamine , 1986, Clinical pharmacology and therapeutics.

[12]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[13]  F. Simons,et al.  The pharmacology and use of H1-receptor-antagonist drugs. , 1994, The New England journal of medicine.

[14]  W. L. Chiou,et al.  Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults , 2004, European Journal of Clinical Pharmacology.

[15]  D. Greenblatt,et al.  Pharmacokinetics of Diphenhydramine and a Demethylated Metabolite Following Intravenous And Oral Administration , 1986, Journal of clinical pharmacology.

[16]  C. Hignite,et al.  Correlation between plasma diphenhydramine level and sedative and antihistamine effects. , 1979, Clinical pharmacology and therapeutics.

[17]  K. Simons,et al.  The pharmacokinetics and antihistaminic effects of brompheniramine. , 1982, The Journal of allergy and clinical immunology.

[18]  C. Hignite,et al.  Correlation between plasma diphenhydramine level and sedative and antihistamine effects , 1978 .

[19]  A. Wellstein,et al.  Chlorpheniramine plasma concentration and histamine H1‐receptor occupancy , 1995, Clinical pharmacology and therapeutics.

[20]  G. Krishna,et al.  Metabolism, tissue distribution and covalent binding of tripelennamine and its N-nitroso derivative in the rat. , 1975, The Journal of pharmacology and experimental therapeutics.

[21]  J. Yeh,et al.  Distribution, excretion, and metabolism of 14C-labeled quaternary ammonium salt of mepazine and promethazine in rats. , 1970, Journal of pharmaceutical sciences.

[22]  K. Simons,et al.  The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. , 1984, The Journal of allergy and clinical immunology.

[23]  L. Bertilsson,et al.  Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. , 1987, Pharmacology & toxicology.

[24]  U. Meyer,et al.  Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism. , 1988, Biochemical pharmacology.

[25]  D. Miller,et al.  Metabolism of chlorpheniramine-3H by the rat and dog. , 1969, Biochemical pharmacology.

[26]  G. Jones,et al.  Site dependence of drug concentrations in postmortem blood--a case study. , 1987, Journal of analytical toxicology.

[27]  G. Alván,et al.  Clinical consequences of polymorphic drug oxidation , 1991, Fundamental & clinical pharmacology.

[28]  R. Nation,et al.  Chlorpheniramine. I. Rapid quantitative analysis of chlorpheniramine in plasma, saliva and urine by high-performance liquid chromatography. , 1979, Journal of chromatography.

[29]  M. Ghoneim,et al.  Diphenhydramine: Kinetics and psychomotor effects in elderly women , 1982, Clinical pharmacology and therapeutics.

[30]  M. Tsuang,et al.  Idiosyncratic pharmacokinetics complicating treatment of major depression in an elderly woman. , 1985, The Journal of nervous and mental disease.

[31]  A. Bacigalupo,et al.  Bolus methylprednisolone in severe aplastic anemia. , 1979, The New England journal of medicine.

[32]  D. Paton,et al.  Clinical Pharmacokinetics of H1-Receptor Antagonists (The Antihistamines) , 1985, Clinical pharmacokinetics.